At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Global/single cell gene expression profiles obtained from Synovial biopsiesprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium
Cliniques universitaires Saint-Luc- Université Catholique de Louvain·interventional·Posted Feb 7, 2020·Updated Sep 18, 2023
In Brief
A clinical study evaluating Global/single cell gene expression profiles obtained from Synovial biopsies for Psoriatic Arthritis. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
This study compare the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after a biologic disease modifying anti-rheumatic drugs (DMARDs)(Adalimumab, Ustekinumab, Guselkumab) in patients with active psoriatic arthritis despite a treatment with a conventional synthetic DMARDs (such as methotrexate).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesBelgium
CollaboratorsJanssen-Cilag International NV, University Hospital, Ghent
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedFeb 2020
Primary CompletionSep 2023
TodayJul 2026
First PostedFeb 7, 2020
Enrollment StartJan 14, 2020
Primary CompletionSep 12, 2023
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.4 years ago
Interventions
Global/single cell gene expression profiles obtained from Synovial biopsiesprocedure
Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.